

Levon M Khachigian

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8830515/levon-m-khachigian-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183
papers

9,527
citations

52
h-index

92
g-index

214
ext. papers

10,722
ext. citations

8.4
avg, IF

6.16
L-index

#	Paper	IF	Citations
183	RNA sequencing identifies genes reliant upon Ser26 in early growth response-1 in vascular endothelial cells exposed to fibroblast growth factor-2.. <i>Vascular Pharmacology</i> , 2022 , 106952	5.9	
182	Early Growth Response-1, an Integrative Sensor in Cardiovascular and Inflammatory Disease. <i>Journal of the American Heart Association</i> , 2021 , 10, e023539	6	4
181	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation. <i>Journal of Inflammation Research</i> , 2021 , 14, 1019-1028	4.8	1
180	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. <i>Nature Communications</i> , 2021 , 12, 3297	17.4	3
179	Truncated YY1 interacts with BASP1 through a 339KLK341 motif in YY1 and suppresses vascular smooth muscle cell growth and intimal hyperplasia after vascular injury. <i>Cardiovascular Research</i> , 2021 , 117, 2395-2406	9.9	1
178	Serine 26 in Early Growth Response-1 Is Critical for Endothelial Proliferation, Migration, and Network Formation. <i>Journal of the American Heart Association</i> , 2021 , 10, e020521	6	2
177	Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. <i>Cancer Letters</i> , 2021 , 522, 57-62	9.9	0
176	Pharmaceutical patents: reconciling the human right to health with the incentive to invent. <i>Drug Discovery Today</i> , 2020 , 25, 1135-1141	8.8	4
175	Remote Ischemic Preconditioning induces Cardioprotective Autophagy and Signals through the IL-6-Dependent JAK-STAT Pathway. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
174	Repurposing Drugs for Skin Cancer. <i>Current Medicinal Chemistry</i> , 2020 , 27, 7214-7221	4.3	2
173	Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/BosB-VCAM-1 axis. <i>Science Advances</i> , 2020 , 6, eaaz7815	14.3	6
172	Comparative transcriptomics of primary cells in vertebrates. <i>Genome Research</i> , 2020 , 30, 951-961	9.7	12
171	Recruitment and maturation of the coronary collateral circulation: Current understanding and perspectives in arteriogenesis. <i>Microvascular Research</i> , 2020 , 132, 104058	3.7	14
170	Neutralizing the pathological effects of extracellular histones with small polyanions. <i>Nature Communications</i> , 2020 , 11, 6408	17.4	17
169	Extracellular signal-regulated kinase-1 phosphorylates early growth response-1 at serine 26. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 510, 345-351	3.4	5
168	The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. <i>Cancer Letters</i> , 2019 , 459, 268-276	9.9	18
167	Transcription Factors Targeted by miRNAs Regulating Smooth Muscle Cell Growth and Intimal Thickening after Vascular Injury. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10

166	Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection. <i>Oncotarget</i> , 2019 , 10, 216-244	3.3	26
165	Deoxyribozymes as Catalytic Nanotherapeutic Agents. <i>Cancer Research</i> , 2019 , 79, 879-888	10.1	22
164	"Summer Shift": A Potential Effect of Sunshine on the Time Onset of ST-Elevation Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	14
163	The Yin and Yang of YY1 in tumor growth and suppression. <i>International Journal of Cancer</i> , 2018 , 143, 460-465	7.5	67
162	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. <i>Oncotarget</i> , 2018 , 9, 21613-21627	3.3	29
161	Promoter Usage and Dynamics in Vascular Smooth Muscle Cells Exposed to Fibroblast Growth Factor-2 or Interleukin-1 <i>Scientific Reports</i> , 2018 , 8, 13164	4.9	6
160	Melanoma protective antitumor immunity activated by catalytic DNA. <i>Oncogene</i> , 2018 , 37, 5115-5126	9.2	11
159	FANTOM5 CAGE profiles of human and mouse samples. <i>Scientific Data</i> , 2017 , 4, 170112	8.2	88
158	Developing Neolignans as Proangiogenic Agents: Stereoselective Total Syntheses and Preliminary Biological Evaluations of the Four Guaiacylglycerol 8--4RConiferyl Ethers. <i>ACS Omega</i> , 2017 , 2, 7375-7388	3.9	5
157	Inhibition of intimal thickening after vascular injury with a cocktail of vascular endothelial growth factor and cyclic Arg-Gly-Asp peptide. <i>International Journal of Cardiology</i> , 2016 , 220, 185-91	3.2	7
156	Early growth response-1 in the pathogenesis of cardiovascular disease. <i>Journal of Molecular Medicine</i> , 2016 , 94, 747-53	5.5	21
155	MicroRNA miR-191 targets the zinc finger transcription factor Egr-1 and suppresses intimal thickening after carotid injury. <i>International Journal of Cardiology</i> , 2016 , 212, 299-302	3.2	12
154	Transcriptional dynamics reveal critical roles for non-coding RNAs in the immediate-early response. <i>PLoS Computational Biology</i> , 2015 , 11, e1004217	5	15
153	Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. <i>Science</i> , 2015 , 347, 1010-4	33.3	384
152	A promoter-level mammalian expression atlas. <i>Nature</i> , 2014 , 507, 462-70	50.4	1301
151	PDGF-D expression is down-regulated by TGFβ in fibroblasts. <i>PLoS ONE</i> , 2014 , 9, e108656	3.7	9
150	Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 2479-88	6.9	29
149	Drug-induced immune thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 521-30	30	24

148	Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). <i>International Journal of Cardiology</i> , 2013 , 168, 3659-64	3.2	9
147	Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). <i>Lancet, The</i> , 2013 , 381, 1835-43	4.0	69
146	DNAzyme delivery approaches in biological settings. <i>Current Medicinal Chemistry</i> , 2013 , 20, 3448-55	4.3	11
145	c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.. <i>Journal of Biological Chemistry</i> , 2013 , 288, 31918	5.4	78
144	Selective inhibition of the master regulator transcription factor Egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. <i>Journal of the American Heart Association</i> , 2013 , 2, e000023	6	21
143	GILZ overexpression inhibits endothelial cell adhesive function through regulation of NF-B and MAPK activity. <i>Journal of Immunology</i> , 2013 , 191, 424-33	5.3	50
142	Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. <i>Blood</i> , 2013 , 122, 2911-9	2.2	48
141	Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. <i>Oncotarget</i> , 2013 , 4, 1373-87	3.3	47
140	Current and potential treatments for cervical cancer. <i>Current Cancer Drug Targets</i> , 2013 , 13, 205-20	2.8	71
139	Therapeutic perspectives on pancreatic cancer. <i>Current Cancer Drug Targets</i> , 2013 , 13, 400-10	2.8	3
138	Insights into Roles of Immediate-Early Genes in Angiogenesis 2013 , 145-162		
137	Platelet-derived growth factor-BB mediates cell migration through induction of activating transcription factor 4 and tenascin-C. <i>American Journal of Pathology</i> , 2012 , 180, 2590-7	5.8	10
136	Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGF β receptor phosphorylation. <i>Archives of Biochemistry and Biophysics</i> , 2012 , 525, 25-31	4.1	13
135	Reduced retinal microvascular density, improved forepaw reach, comparative microarray and gene set enrichment analysis with c-jun targeting DNA enzyme. <i>PLoS ONE</i> , 2012 , 7, e39160	3.7	7
134	SUMOylation regulates the transcriptional repression activity of FOG-2 and its association with GATA-4. <i>PLoS ONE</i> , 2012 , 7, e50637	3.7	10
133	Intracoronary delivery of DNAzymes targeting human EGR-1 reduces infarct size following myocardial ischaemia reperfusion. <i>Journal of Pathology</i> , 2012 , 227, 157-64	9.4	20
132	Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 2597-606	4.7	35
131	Succinobucol induces apoptosis in vascular smooth muscle cells. <i>Free Radical Biology and Medicine</i> , 2012 , 52, 871-9	7.8	7

130	Repression of PDGF-R β after cellular injury involves TNF- α formation of a c-Fos-YY1 complex, and negative regulation by HDAC. <i>American Journal of Physiology - Cell Physiology</i> , 2012 , 302, C1590-8	5.4	7
129	DNAzyme targeting c-jun suppresses skin cancer growth. <i>Science Translational Medicine</i> , 2012 , 4, 139ra827.5	27.5	44
128	Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1. <i>International Journal of Oncology</i> , 2012 , 40, 1575-80	4.4	11
127	IL-1beta signals through the EGF receptor and activates Egr-1 through MMP-ADAM. <i>PLoS ONE</i> , 2012 , 7, e39811	3.7	15
126	Nuclear import of early growth response-1 involves importin-7 and the novel nuclear localization signal serine-proline-serine. <i>International Journal of Biochemistry and Cell Biology</i> , 2011 , 43, 905-12	5.6	21
125	Divergent roles of NF- κ B and Egr-1 in flow-dependent restenosis after angioplasty and stenting. <i>Atherosclerosis</i> , 2011 , 214, 65-72	3.1	4
124	Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'RTR. <i>Cancer Cell</i> , 2011 , 20, 200-13	24.3	136
123	Emerging therapeutic approaches in the management of retinal angiogenesis and edema. <i>Journal of Molecular Medicine</i> , 2011 , 89, 343-61	5.5	22
122	Recent developments in drug-eluting stents. <i>Journal of Molecular Medicine</i> , 2011 , 89, 545-53	5.5	13
121	Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 536-45	9.4	31
120	TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. <i>Circulation Research</i> , 2010 , 106, 1061-71	15.7	64
119	Interplay between heme oxygenase-1 and the multifunctional transcription factor yin yang 1 in the inhibition of intimal hyperplasia. <i>Circulation Research</i> , 2010 , 107, 1490-7	15.7	29
118	Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. <i>Journal of Immunology</i> , 2010 , 185, 1238-47	5.3	80
117	c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins. <i>Journal of Biological Chemistry</i> , 2010 , 285, 4038-4048	5.4	21
116	PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. <i>Endocrinology</i> , 2010 , 151, 4356-67	4.8	47
115	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 729-34	3.4	46
114	Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. <i>Blood</i> , 2010 , 116, 1958-60	2.2	16
113	Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway. <i>Haematologica</i> , 2010 , 95, 1745-53	6.6	32

112	Activation transcription factor-4 and the acute vascular response to injury. <i>Journal of Molecular Medicine</i> , 2010 , 88, 545-52	5.5	15
111	Angiotensin II-inducible smooth muscle cell apoptosis involves the angiotensin II type 2 receptor, GATA-6 activation, and FasL-Fas engagement. <i>Circulation Research</i> , 2009 , 105, 422-30	15.7	28
110	Histone deacetylase-1 is enriched at the platelet-derived growth factor-D promoter in response to interleukin-1beta and forms a cytokine-inducible gene-silencing complex with NF-kappaB p65 and interferon regulatory factor-1. <i>Journal of Biological Chemistry</i> , 2009 , 284, 35101-12	5.4	8
109	Injury-induced platelet-derived growth factor receptor-alpha expression mediated by interleukin-1beta (IL-1beta) release and cooperative transactivation by NF-kappaB and ATF-4: IL-1beta facilitates HDAC-1/2 dissociation from promoter. <i>Journal of Biological Chemistry</i> , 2009 , 284, 27933-27943	5.4	8
108	Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 209-16	9.4	63
107	A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. <i>Molecular Cancer Research</i> , 2009 , 7, 755-64	6.6	40
106	c-Jun DNazymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1836-42	9.4	33
105	Sp1 phosphorylation and its regulation of gene transcription. <i>Molecular and Cellular Biology</i> , 2009 , 29, 2483-8	4.8	246
104	Related transcriptional enhancer factor-1 induces fibroblast growth factor receptor-1 expression in endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 380, 689-94	3.4	
103	DNAzyme technology and cancer therapy: cleave and let die. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 243-51	6.1	117
102	Angiotensin II induction of PDGF-C expression is mediated by AT1 receptor-dependent Egr-1 transactivation. <i>Nucleic Acids Research</i> , 2008 , 36, 1941-51	20.1	18
101	c-Jun knockdown sensitizes osteosarcoma to doxorubicin. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1909-12	6.1	32
100	TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. <i>Journal of Biological Chemistry</i> , 2008 , 283, 7754-62	5.4	73
99	Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury. <i>Circulation Research</i> , 2008 , 103, 378-87	15.7	42
98	c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. <i>Molecular Cancer Research</i> , 2008 , 6, 1289-92	6.6	26
97	Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. <i>Journal of Microencapsulation</i> , 2008 , 25, 421-5	3.4	27
96	Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1297-301	4.6	23
95	Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1033-6	4.6	26

94	Angiotensin II-inducible platelet-derived growth factor-D transcription requires specific Ser/Thr residues in the second zinc finger region of Sp1. <i>Circulation Research</i> , 2008 , 102, e38-51	15.7	27
93	Immediate-early genes as master switches in disease. <i>Cell Biology International</i> , 2008 , 32, S3-S3	4.5	
92	Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1. <i>Journal of Cellular Biochemistry</i> , 2007 , 100, 1526-35	4.7	27
91	Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly. <i>Circulation Research</i> , 2007 , 101, 146-55	15.7	56
90	The streptozotocin-treated Sprague-Dawley rat: a useful model for the assessment of acute and chronic effects of myocardial ischaemia reperfusion injury in experimental diabetes. <i>Diabetes and Vascular Disease Research</i> , 2007 , 4, 153-4	3.3	2
89	Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. <i>Biochemical Journal</i> , 2007 , 407, 79-87	3.8	46
88	The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting. <i>Atherosclerosis</i> , 2007 , 194, 364-71	3.1	10
87	Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. <i>American Journal of Pathology</i> , 2007 , 171, 1079-88	5.8	105
86	Early growth response-1 in cardiovascular pathobiology. <i>Circulation Research</i> , 2006 , 98, 186-91	15.7	224
85	The Endothelium and Cardiovascular Disease: New Developments, New Challenges. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2006 , 13, 365-365		
84	JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. <i>Journal of Cell Science</i> , 2006 , 119, 3219-26	5.3	23
83	Collagen antibody-induced arthritis. <i>Nature Protocols</i> , 2006 , 1, 2512-6	18.8	109
82	Rat models of myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 602-610	7	46
81	Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. <i>Blood</i> , 2006 , 107, 2322-9	2.2	29
80	Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. <i>Nature Biotechnology</i> , 2006 , 24, 856-63	44.5	94
79	Peroxide-inducible Ets-1 mediates platelet-derived growth factor receptor-alpha gene transcription in vascular smooth muscle cells. <i>American Journal of Pathology</i> , 2005 , 167, 1149-59	5.8	22
78	Fibroblast growth factor 2 and the transcription factor Egr-1 localise to endothelial cell microvascular channels in human coronary artery occlusion. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 172-174		7
77	Galectin-1 interacts with the $\alpha 5 \beta 1$ fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. <i>Journal of Biological Chemistry</i> , 2005 , 280, 37266-77	5.4	137

76	Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. <i>Journal of Biological Chemistry</i> , 2005 , 280, 35136-47	5.4	67
75	Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. <i>Cardiovascular Drug Reviews</i> , 2004 , 22, 1-6		56
74	Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. <i>Journal of Biological Chemistry</i> , 2004 , 279, 2377-82	5.4	66
73	Early Growth Response-1: Blocking Angiogenesis by Shooting the Messenger. <i>Cell Cycle</i> , 2004 , 3, 9-10	4.7	17
72	Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNazymes targeting the zinc finger transcription factor EGR-1. <i>Nucleic Acids Research</i> , 2004 , 32, 3065-9	20.1	97
71	Protein-Protein Interaction between Fli-1 and GATA-1 Mediates Synergistic Expression of Megakaryocyte-Specific Genes through Cooperative DNA Binding. <i>Molecular and Cellular Biology</i> , 2004 , 24, 5088-5088	4.8	78
70	Fibroblast growth factor-2 induction of platelet-derived growth factor-C chain transcription in vascular smooth muscle cells is ERK-dependent but not JNK-dependent and mediated by Egr-1. <i>Journal of Biological Chemistry</i> , 2004 , 279, 40289-95	5.4	43
69	Oxidative Stress and Endothelial Dysfunction. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2004 , 11, 77-78		1
68	Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. <i>Circulation Research</i> , 2004 , 95, 479-87	15.7	41
67	Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. <i>Nucleic Acids Research</i> , 2004 , 32, 2281-5	20.1	39
66	Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 683-96	9.7	136
65	Modulation of growth factor gene expression in vascular cells by oxidative stress. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2004 , 11, 133-9		49
64	DNazymes as molecular agents that manipulate Egr-1 gene expression. <i>Biochemical Pharmacology</i> , 2004 , 68, 1023-5	6	1
63	Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1) transcription by Sp1 is mediated via distinct cis-acting positive and negative regulatory elements in the proximal p21(WAF1/Cip1) promoter. <i>Journal of Cellular Biochemistry</i> , 2004 , 93, 304-16	4.7	13
62	The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. <i>American Journal of Pathology</i> , 2004 , 165, 331-40	5.8	39
61	Low flow promotes intimal hyperplasia. Comparison with lumen loss in balloon-injured and uninjured vessels and the effects of the antioxidant pyrrolidine dithiocarbamate. <i>Atherosclerosis</i> , 2004 , 177, 269-74	3.1	2
60	Deoxyribozymes as inhibitors of vascular smooth muscle cell growth. <i>Current Pharmaceutical Biotechnology</i> , 2004 , 5, 337-9	2.6	2
59	Early growth response-1: blocking angiogenesis by shooting the messenger. <i>Cell Cycle</i> , 2004 , 3, 10-1	4.7	7

58	ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. <i>Journal of Cellular Biochemistry</i> , 2003 , 89, 289-300	4.7	93
57	Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. <i>Nature Medicine</i> , 2003 , 9, 1026-32	50.5	294
56	Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. <i>Molecular and Cellular Biology</i> , 2003 , 23, 3427-41	4.8	101
55	Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. <i>Journal of Biological Chemistry</i> , 2003 , 278, 32537-43	5.4	64
54	Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. <i>Journal of Biological Chemistry</i> , 2003 , 278, 50377-85	5.4	64
53	Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1394-403	9.7	86
52	Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. <i>Circulation Research</i> , 2003 , 92, e70-7	15.7	50
51	Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip1: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF1/Cip1 promoter. <i>Journal of Biological Chemistry</i> , 2003 , 278, 27863-9	5.4	40
50	Novel and emerging therapies in cardiology and haematology. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2003 , 3, 101-23		1
49	Coating Stents With Antirestenotic Drugs: The Blunderbuss or the Magic Bullet?. <i>Circulation</i> , 2002 , 105,	16.7	3
48	Catalytic Antisense DNA Molecules Targeting Egr-1 Inhibit Neointima Formation following Permanent Ligation of Rat Common Carotid Arteries. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 134-140	7	43
47	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. <i>Journal of Cellular Biochemistry</i> , 2002 , 84, 575-582	4.7	26
46	von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. <i>Journal of Cellular Biochemistry</i> , 2002 , 85, 490-5	4.7	15
45	NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. <i>EMBO Journal</i> , 2002 , 21, 334-43	13	41
44	Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. <i>Journal of Biological Chemistry</i> , 2002 , 277, 36244-52	5.4	55
43	c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. <i>Journal of Biological Chemistry</i> , 2002 , 277, 22985-91	5.4	86
42	Coronary in-stent restenosis: current status and future strategies. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 183-93	15.1	279
41	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. <i>Journal of Cellular Biochemistry</i> , 2002 , 84, 575-82	4.7	9

40	Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet?. <i>Circulation</i> , 2002 , 105, E29	16.7	3
39	Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 134-40	7	14
38	DNAzymes: cutting a path to a new class of therapeutics. <i>Current Opinion in Molecular Therapeutics</i> , 2002 , 4, 119-21		19
37	Catalytic oligonucleotides targeting EGR-1 as potential inhibitors of in-stent restenosis. <i>Annals of the New York Academy of Sciences</i> , 2001 , 947, 412-5	6.5	4
36	Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. <i>Journal of Molecular Medicine</i> , 2001 , 79, 695-706	5.5	42
35	Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. <i>Journal of Cellular Biochemistry</i> , 2001 , 81, 523-34	4.7	43
34	Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury. Autocrine/paracrine role of endogenous fibroblast growth factor-2. <i>Journal of Biological Chemistry</i> , 2001 , 276, 41143-9	5.4	38
33	Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. <i>Circulation Research</i> , 2001 , 89, 670-7	15.7	100
32	Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-zeta. <i>Nucleic Acids Research</i> , 2001 , 29, 1027-33	20.1	55
31	Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. <i>Journal of Biological Chemistry</i> , 2001 , 276, 4964-71	5.4	63
30	Acute Local Release of Fibroblast Growth Factor-2 but not Transforming Growth Factor- β following Coronary Stenting. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 574-576	7	10
29	Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression. <i>Molecular and Cellular Biochemistry</i> , 2000 , 212, 183-186	4.2	9
28	The role of platelet α granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. <i>Blood</i> , 2000 , 95, 3094-3101	2.2	79
27	Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. <i>Journal of Biological Chemistry</i> , 2000 , 275, 16709-16	5.4	83
26	Novel negative regulatory element in the platelet-derived growth factor B chain promoter that mediates ERK-dependent transcriptional repression. <i>Journal of Biological Chemistry</i> , 2000 , 275, 11478-83	5.4	3
25	Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1189-95	15.9	47
24	Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression 2000 , 183-186		
23	Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. <i>Journal of Biological Chemistry</i> , 1999 , 274, 22784-93	5.4	42

22	GC factor 2 represses platelet-derived growth factor A-chain gene transcription and is itself induced by arterial injury. <i>Circulation Research</i> , 1999 , 84, 1258-67	15.7	50
21	New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. <i>Nature Medicine</i> , 1999 , 5, 1264-9	50.5	213
20	Left main coronary artery stenosis after percutaneous transluminal coronary angioplasty: importance of remaining "minimally invasive". <i>Catheterization and Cardiovascular Interventions</i> , 1999 , 46, 254-5	2.7	4
19	Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. <i>American Journal of Pathology</i> , 1999 , 155, 897-905	5.8	54
18	Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. <i>American Journal of Pathology</i> , 1999 , 155, 1311-7	5.8	44
17	Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. <i>American Journal of Pathology</i> , 1999 , 154, 937-44	5.8	105
16	Regulation of PDGF-B in endothelial cells exposed to cyclic strain. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 349-55	9.4	52
15	Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats. <i>Journal of Biological Chemistry</i> , 1998 , 273, 5758-64	5.4	44
14	Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2280-6	9.4	165
13	Hemodynamics, endothelial gene expression, and atherogenesis. <i>Annals of the New York Academy of Sciences</i> , 1997 , 811, 1-10; discussion 10-1	6.5	92
12	FGF-1-induced platelet-derived growth factor-A chain gene expression in endothelial cells involves transcriptional activation by early growth response factor-1. <i>Circulation Research</i> , 1997 , 81, 282-8	15.7	43
11	Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. <i>Circulation Research</i> , 1997 , 81, 457-61	15.7	120
10	Endothelial gene regulation by laminar shear stress. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 430, 155-64	3.6	85
9	Extracellular matrix is a source of mitogenically active platelet-derived growth factor. <i>Journal of Cellular Physiology</i> , 1996 , 168, 322-32	7	14
8	Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. <i>Journal of Biological Chemistry</i> , 1995 , 270, 28903-9	5.4	103
7	Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. <i>Journal of Biological Chemistry</i> , 1995 , 270, 27679-86	5.4	244
6	Isolation and characterization of a novel zinc-finger protein with transcription repressor activity. <i>Journal of Biological Chemistry</i> , 1995 , 270, 22143-52	5.4	94
5	Structural basis for the extracellular retention of PDGF A-chain using a synthetic peptide corresponding to exon 6. <i>Peptides</i> , 1994 , 15, 133-7	3.8	12

4	Platelet-derived growth factor and alternative splicing: a review. <i>Pathology</i> , 1992 , 24, 280-90	1.6	18
3	A crossreactive antipeptide monoclonal antibody with specificity for lysyl-lysine. <i>Journal of Immunological Methods</i> , 1991 , 140, 249-58	2.5	8
2	Early Growth Response-1 Coupling in Vascular Endothelium818-821		
1	The Yin and Yang of YY1 in tumor growth and suppression		1